Novel and reported compensatory mutations in
Mycobacterium tuberculosis
antibiotic resistance
compensatory mutations
fitness
rifampicin
tuberculosis
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
07
2023
accepted:
19
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Rifampicin (RIF) is a key first-line drug used to treat tuberculosis, a primarily pulmonary disease caused by We performed an association study on a globally representative set of 4,309 whole genome sequenced clinical Of the 1,079 RIF resistant isolates, 638 carried previously reported putative and high-probability compensatory mutations. Our strict criteria identified 46 additional mutations in
Sections du résumé
Background
UNASSIGNED
Rifampicin (RIF) is a key first-line drug used to treat tuberculosis, a primarily pulmonary disease caused by
Objectives
UNASSIGNED
We performed an association study on a globally representative set of 4,309 whole genome sequenced clinical
Results and conclusions
UNASSIGNED
Of the 1,079 RIF resistant isolates, 638 carried previously reported putative and high-probability compensatory mutations. Our strict criteria identified 46 additional mutations in
Identifiants
pubmed: 38260909
doi: 10.3389/fmicb.2023.1265390
pmc: PMC10800992
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1265390Informations de copyright
Copyright © 2024 Conkle-Gutierrez, Ramirez-Busby, Gorman, Elghraoui, Hoffner, Elmaraachli and Valafar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.